Cargando…
Bupivacaine inhibits the malignant biological behavior of oral squamous cell carcinoma cells by inhibiting the activation of ERK1/2 and STAT3
BACKGROUND: Oral squamous cell carcinoma (OSCC) is an aggressive malignant tumor. Bupivacaine (Bupi), a local anesthetic drug, has been shown to display anti-tumor activity against a variety of tumors. METHODS: We selected OSCC CAL-27 cells as the in vitro model. Cell toxicity, proliferation, apopto...
Autores principales: | Wang, Zhongchao, Zhang, Jie, Wen, Yongmei, Wang, Pin, Fan, Liyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184410/ https://www.ncbi.nlm.nih.gov/pubmed/34164473 http://dx.doi.org/10.21037/atm-21-1414 |
Ejemplares similares
-
STAT1 inhibits STAT3 activation in esophageal squamous cell carcinoma
por: Liu, Zhaoyong, et al.
Publicado: (2018) -
Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma
por: Brown, Megan E., et al.
Publicado: (2015) -
Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation
por: Ji, Yubin, et al.
Publicado: (2019) -
Icaritin Reduces Oral Squamous Cell Carcinoma Progression via the Inhibition of STAT3 Signaling
por: Yang, Jian-Guang, et al.
Publicado: (2017) -
ERK expression and its correlation with STAT1 in esophageal squamous cell carcinoma
por: Wang, Hu, et al.
Publicado: (2017)